The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

Cytokine Growth Factor Rev. 2020 Aug:54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.

Abstract

Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.

Keywords: COVID-19; Cytokine storm; JAK/STAT pathway; Ruxolitinib; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / pathology
  • Cytokine Release Syndrome / drug therapy
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors*
  • Janus Kinase 2 / antagonists & inhibitors*
  • Janus Kinase Inhibitors / therapeutic use*
  • Nitriles
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Risk Factors
  • SARS-CoV-2
  • STAT Transcription Factors / antagonists & inhibitors
  • Signal Transduction / drug effects

Substances

  • Antiviral Agents
  • Janus Kinase Inhibitors
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT Transcription Factors
  • ruxolitinib
  • JAK1 protein, human
  • JAK2 protein, human
  • Janus Kinase 1
  • Janus Kinase 2